Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00064402 · ClinicalTrials.gov registry record · Phase 3
Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD
A Phase 3 study of Chronic Obstructive Pulmonary Disease and Emphysema, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 741
- Enrollment target
- 20
- Study locations
NCT00064402: Completed Phase 3 study of Chronic Obstructive Pulmonary Disease and Emphysema, sponsored by Sumitomo Pharma America.
NCT00064402 is a Phase 3 study of Chronic Obstructive Pulmonary Disease and Emphysema that has completed, run by Sumitomo Pharma America. The registered enrollment target is 741 participants, below the 1,745-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (58% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00064402, a Phase 3 study of Chronic Obstructive Pulmonary Disease and Emphysema, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 741 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the bronchodilator effect and safety of multiple daily doses of arformoterol administered for 12 weeks as maintenance treatment in patients with COPD
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Salmeterol
- DRUG arformoterol tartrate inhalation solution
Study Locations (20)
California
- Northern California Research Corp. - Fair Oaks
- SARC Research Center - Fresno
- California Research Medical Group, Inc. - Fullerton
- Radiant Research-Irvine - Irvine
- West Coast Clinical Trials - Newport Beach
- Center for Clinical Trials, LLC - Paramount
- Advances in Medicine - Rancho Mirage
- Institute of Healthcare Assessment, Inc. - San Diego
- San Jose Clinical Research - San Jose
- Allergy & Asthma Medical Group of Diablo Valley, Inc. - Walnut Creek
Florida
- Clinical Research of West Florida, Inc. - Clearwater
- University Clinical Research, DeLand - DeLand
- Mt. Sinai Medical Center - Miami Beach
Arizona
- Pulmonary Associates, PA - Phoenix
- Arizona Clinical Research Center, Inc. - Tucson
Colorado
- Colorado Pulmonary Associates - Denver
- Northern Colorado Pulmonary Consultants, PC - Fort Collins
Alabama
- Pulmonary & Sleep Associates of Jasper, PC - Jasper
Connecticut
- Physicians Research Center, Inc. - Hartford
District of Columbia
- Washington Hospital Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 741 participants |
| Start Date | 2002-04 |
| Est. Completion | 2004-03 |
| Phase | Phase 3 |
What the finished NCT00064402 record still lists
NCT00064402 is an interventional study that assigns participants to a tested intervention. The registered 741 participants enrollment target is mid-sized for trials with a published cap, below the 1,745-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (58% lower).
The record links to 3 conditions, with Chronic Obstructive Pulmonary Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00064402 names 20 study sites across 7 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT00064402 about?
NCT00064402 is a clinical study titled "Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD". The purpose of this study is to assess the bronchodilator effect and safety of multiple daily doses of arformoterol administered for 12 weeks as maintenance treatment in patients with COPD
What is the current status of trial NCT00064402?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 741 participants. The study started on 2002-04. Estimated completion is 2004-03.
What conditions does trial NCT00064402 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease, Emphysema, Chronic Bronchitis.
What interventions are being tested in trial NCT00064402?
The interventions under investigation include: Placebo (DRUG), Salmeterol (DRUG), arformoterol tartrate inhalation solution (DRUG).
Who is sponsoring clinical trial NCT00064402?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00064402 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00064402's enrollment target sits among peer trials
741 20th of 86 higher than 67 of 86 other Chronic Obstructive Pulmonary Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Obstructive Pulmonary Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
RECRUITING · Phase 3
-
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
RECRUITING · Phase 3
-
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
RECRUITING · Phase 3
-
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
ACTIVE NOT RECRUITING · Phase 3
-
A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 3
-
Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05786417 · 741 participants · Phase 4
LIVEBETTER: A Trial Comparing Medications in Older Adults With Stable Angina and Multiple Chronic Conditions
- NCT06556563 · 741 participants · Phase 3
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
- NCT03963622 · 740 participants · NA
Careful Ventilation in Acute Respiratory Distress Syndrome (COVID-19 and Non-COVID-19)
- NCT04074135 · 740 participants · Phase 2
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia